NCT04314076

Brief Summary

This study will enroll patients with Multiple Sclerosis and some difficulty with walking. The purpose of this study is to use Rhythmic Auditory Stimulation (RAS) a music therapy technique that provides rhythmic auditory cues (like a beat) to help improve a patient's movements, especially when walking. Participants will be asked to participate in a walking program (WP) with Rhythmic Auditory Stimulation (RAS), or a WP without RAS.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for not_applicable multiple-sclerosis

Timeline
Completed

Started Jun 2020

Typical duration for not_applicable multiple-sclerosis

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 11, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 18, 2020

Completed
3 months until next milestone

Study Start

First participant enrolled

June 8, 2020

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 7, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 7, 2022

Completed
Last Updated

February 9, 2023

Status Verified

February 1, 2023

Enrollment Period

2.4 years

First QC Date

March 11, 2020

Last Update Submit

February 7, 2023

Conditions

Keywords

Gait analysisMusic therapyMultiple sclerosis

Outcome Measures

Primary Outcomes (2)

  • Number of patients with adverse events

    Adverse events will be collected throughout the study period to assess treatment safety.

    through study completion, up to 16 weeks

  • Percentage of training sessions missed.

    Training session attendance will be tracked as an indicator of feasibility throughout the treatment period.

    through end of treatment, up to 9 weeks

Secondary Outcomes (4)

  • Timed 25 Foot Walk

    Week 0, Week 9 and week 16

  • 6-Minute Walk

    Week 0, Week 9 and week 16

  • Spatiotemporal gait parameters

    Week 0, Week 9 and week 16

  • MS Walking Scale - 12

    Week 0, Week 9 and week 16

Study Arms (2)

Gait Training (GT) with Rhythmic Auditory Stimulation (RAS)

ACTIVE COMPARATOR

Participants in this arm will complete 16 supervised gait training sessions consisting of continuous overground walking on a track for 30 minutes,with RAS

Other: Rhythmic auditory stimulation

Gait training (GT) without Rhythmic Auditory Stimulation (RAS)

OTHER

Participants in this arm will complete 16 supervised gait training sessions consisting of continuous overground walking on a track for 30 minutes without RAS

Other: Gait Training

Interventions

RAS, a Neurologic Music Therapy technique developed to utilize rhythm and timing cues to assist in improving the basic, intrinsic rhythmic movements of gait.

Also known as: RAS
Gait Training (GT) with Rhythmic Auditory Stimulation (RAS)

Continuous overground walking on a track for 30 minutes. Gait training will primarily consist of walking exercise under the supervision of an exercise physiologist.

Also known as: GT
Gait training (GT) without Rhythmic Auditory Stimulation (RAS)

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of MS based on 2017 revised McDonald criteria (relapsing or progressive course)
  • Performs the T25FW in 8 to 30 seconds (cane(s), walking stick(s), crutch(es), or wheeled walker allowed)

You may not qualify if:

  • Physical therapy in the past 3 months or immediate need for PT due to safety concerns (e.g. falls)
  • Requires at least one seated rest during the 6 MW test
  • Treatment with high-dose corticosteroids in the past 2 months or planned during the study period
  • Lower extremity botulinum toxin (BT) injections for spasticity in the past 3 months, or planned during the study period
  • Initiation of an oral symptomatic therapy which could affect walking in the past 4 weeks (particularly dalfampridine and medications for spasticity)
  • Initiation of a new disease-modifying therapy for MS in the past 3 months
  • Comorbidity compromising safe participation or affecting walking (e.g. uncontrolled cardiac or respiratory illness, musculoskeletal disorder)
  • Severe hearing impairment with or without the use of hearing aids, such that the participant cannot hear the rhythmic music stimulus consistently.
  • Inability to walk safely to the rhythmic music stimulus during the baseline visit.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cleveland Clinic

Cleveland, Ohio, 44195, United States

Location

MeSH Terms

Conditions

Multiple SclerosisGait Disorders, Neurologic

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating DiseasesAutoimmune DiseasesImmune System DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Francois Bethoux, MD

    The Cleveland Clinic

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
A blinded examiner will be used to perform the gait analysis, 6 minute walk , and timed 25 foot walk
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: a single blind parallel-group pilot randomized controlled trial comparing rhythmic auditory stimulation (RAS) with gait training to gait training without RAS.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chairman, Department of PM&R,

Study Record Dates

First Submitted

March 11, 2020

First Posted

March 18, 2020

Study Start

June 8, 2020

Primary Completion

November 7, 2022

Study Completion

November 7, 2022

Last Updated

February 9, 2023

Record last verified: 2023-02

Data Sharing

IPD Sharing
Will not share

Locations